Literature DB >> 28928130

Roles for Innate Immunity in Combination Immunotherapies.

Kelly D Moynihan1,2,3, Darrell J Irvine4,2,3,5,6.   

Abstract

Immunity to infectious agents involves a coordinated response of innate and adaptive immune cells working in concert, with many feed-forward and regulatory interactions between both arms of the immune system. In contrast, many therapeutic strategies to augment immunity against tumors have focused predominantly on stimulation of adaptive immunity. However, a growing appreciation of the potential contributions of innate immune effectors to antitumor immunity, especially in the context of combination immunotherapy, is leading to novel strategies to elicit a more integrated immune response against cancer. Here we review antitumor activities of innate immune cells, mechanisms of their synergy with adaptive immune responses against tumors, and discuss recent studies highlighting the potential of combination therapies recruiting both innate and adaptive immune effectors to eradicate established tumors. Cancer Res; 77(19); 5215-21. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28928130      PMCID: PMC5647817          DOI: 10.1158/0008-5472.CAN-17-1340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Authors:  Manisha Singh; Hiep Khong; Zhimin Dai; Xue-Fei Huang; Jennifer A Wargo; Zachary A Cooper; John P Vasilakos; Patrick Hwu; Willem W Overwijk
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

Review 2.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

3.  Allogeneic natural killer cells for refractory lymphoma.

Authors:  Veronika Bachanova; Linda J Burns; David H McKenna; Julie Curtsinger; Angela Panoskaltsis-Mortari; Bruce R Lindgren; Sarah Cooley; Daniel Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2010-08-03       Impact factor: 6.968

4.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

5.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

Review 6.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 7.  The role of myeloid cells in cancer therapies.

Authors:  Camilla Engblom; Christina Pfirschke; Mikael J Pittet
Journal:  Nat Rev Cancer       Date:  2016-07       Impact factor: 60.716

8.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Authors:  Kelly D Moynihan; Cary F Opel; Gregory L Szeto; Alice Tzeng; Eric F Zhu; Jesse M Engreitz; Robert T Williams; Kavya Rakhra; Michael H Zhang; Adrienne M Rothschilds; Sudha Kumari; Ryan L Kelly; Byron H Kwan; Wuhbet Abraham; Kevin Hu; Naveen K Mehta; Monique J Kauke; Heikyung Suh; Jennifer R Cochran; Douglas A Lauffenburger; K Dane Wittrup; Darrell J Irvine
Journal:  Nat Med       Date:  2016-10-24       Impact factor: 53.440

9.  Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Authors:  Laurent Boissel; Monica Betancur-Boissel; Weiquan Lu; Daniela S Krause; Richard A Van Etten; Winfried S Wels; Hans Klingemann
Journal:  Oncoimmunology       Date:  2013-10-22       Impact factor: 8.110

10.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701

View more
  22 in total

Review 1.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

2.  Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).

Authors:  Rogelio Medina; Herui Wang; Veronika Caisová; Jing Cui; Iris H Indig; Ondrej Uher; Juan Ye; Anthony Nwankwo; Victoria Sanchez; Tianxia Wu; Edjah Nduom; John Heiss; Mark R Gilbert; Masaki Terabe; Winson Ho; Jan Zenka; Karel Pacak; Zhengping Zhuang
Journal:  Adv Ther (Weinh)       Date:  2020-06-09

Review 3.  Computational approaches for characterizing the tumor immune microenvironment.

Authors:  Candace C Liu; Chloé B Steen; Aaron M Newman
Journal:  Immunology       Date:  2019-10       Impact factor: 7.397

4.  Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses.

Authors:  Jesse M Jaynes; Rushikesh Sable; Michael Ronzetti; Wendy Bautista; Zachary Knotts; Abisola Abisoye-Ogunniyan; Dandan Li; Raul Calvo; Myagmarjav Dashnyam; Anju Singh; Theresa Guerin; Jason White; Sarangan Ravichandran; Parimal Kumar; Keyur Talsania; Vicky Chen; Anghesom Ghebremedhin; Balasubramanyam Karanam; Ahmad Bin Salam; Ruksana Amin; Taivan Odzorig; Taylor Aiken; Victoria Nguyen; Yansong Bian; Jelani C Zarif; Amber E de Groot; Monika Mehta; Lixin Fan; Xin Hu; Anton Simeonov; Nathan Pate; Mones Abu-Asab; Marc Ferrer; Noel Southall; Chan-Young Ock; Yongmei Zhao; Henry Lopez; Serguei Kozlov; Natalia de Val; Clayton C Yates; Bolormaa Baljinnyam; Juan Marugan; Udo Rudloff
Journal:  Sci Transl Med       Date:  2020-02-12       Impact factor: 17.956

5.  Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs.

Authors:  Christian R Palmer; Max E Jacobson; Olga Fedorova; Anna M Pyle; John T Wilson
Journal:  Bioconjug Chem       Date:  2018-01-19       Impact factor: 4.774

Review 6.  Bioinspired nucleic acid structures for immune modulation.

Authors:  Cameron Louttit; Kyung Soo Park; James J Moon
Journal:  Biomaterials       Date:  2019-06-19       Impact factor: 12.479

7.  Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.

Authors:  Lauren E Milling; Daniel Garafola; Yash Agarwal; Shengwei Wu; Ayush Thomas; Nathan Donahue; Josetta Adams; Nikki Thai; Heikyung Suh; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2021-10-22       Impact factor: 11.151

8.  Stroma-derived ANGPTL2 establishes an anti-tumor microenvironment during intestinal tumorigenesis.

Authors:  Haruki Horiguchi; Tsuyoshi Kadomatsu; Keishi Miyata; Kazutoyo Terada; Michio Sato; Daisuke Torigoe; Jun Morinaga; Toshiro Moroishi; Yuichi Oike
Journal:  Oncogene       Date:  2020-10-13       Impact factor: 9.867

9.  Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.

Authors:  Colin G Buss; Sangeeta N Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-03       Impact factor: 11.205

Review 10.  Innate Immunity Cells and the Neurovascular Unit.

Authors:  Ivan Presta; Marco Vismara; Fabiana Novellino; Annalidia Donato; Paolo Zaffino; Elisabetta Scali; Krizia Caterina Pirrone; Maria Francesca Spadea; Natalia Malara; Giuseppe Donato
Journal:  Int J Mol Sci       Date:  2018-12-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.